By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Santen, Inc. 

2100 Powell Street

Emeryville  California  94608  U.S.A.
Phone: 415-268-9100 Fax: 510-655-5682

Santen Incorporated, a wholly owned subsidiary of Santen Pharmaceutical Co., Ltd., opened its doors in the San Francisco Bay Area in 1993. The company was founded in 1890 in Osaka, Japan, Santen is one of the oldest prescription ophthalmic companies in the world today.

For nearly 120 years, Santen has aimed to refine, innovate, and deliver groundbreaking treatments in the field of ophthalmology. But developing next-generation pharmaceuticals that improve patient quality of life is just part of our mission. With cutting-edge research facilities in the United States, Europe, China, as well as Japan—we consider ourselves global citizens doing our part to expand therapeutic options worldwide.

Our Mission
By focusing our efforts on ophthalmology and related areas, we develop scientific knowledge and organizational capabilities which are unique and original to Santen. We use our unique capabilities to contribute to patients and their loved ones, and consequently to society.

Key Statistics

Ownership: Private

Web Site: Santen, Inc.


Company News
European Medicines Agency Accepts Santen, Inc.'s Marketing Application Filing For Intravitreal Sirolimus For The Treatment Of Noninfectious Uveitis Of The Posterior Segment 3/2/2015 7:22:34 AM
DURECT Corporation (DRRX) Enters Into License Agreement Granting Santen, Inc. The Worldwide Rights To A Sustained Release SABER Ophthalmology Product 12/16/2014 8:25:50 AM
NicOx SA (COX.PA): Santen, Inc. Grants EuPharmed Extension Of Exclusive Rights To Distribute Cationorm® In Italy 5/30/2014 9:10:52 AM
Santen, Inc. Phase 3 Study Meets Primary Endpoint For The Treatment Of Non-Infectious Posterior Segment Uveitis (NI-PSU) 4/4/2014 8:22:06 AM
Santen Pharmaceutical Announces the Appointment of Naveed Shams, M.D., Ph.D. as the President and CEO 3/12/2013 9:39:52 AM
Santen, Inc. Announces FDA Orphan Drug Status for Sirolimus (DE-109) 11/10/2011 8:44:51 AM
Santen, Inc. Announces European Medicines Evaluation Agency Orphan Drug Status for Sirolimus (DE-109) 9/8/2011 9:58:00 AM
Clinical Data, Inc. Receives Notice of IND Filing by Santen, Inc. and Upcoming $2 Million Milestone Payment for A2A Agonist Development Program Focused on Glaucoma Treatments 12/22/2010 7:00:19 AM
Merck & Co., Inc. (MRK) and Santen, Inc. Sign Licensing Agreement In Ophthalmology 4/15/2009 9:55:26 AM
Santen, Inc. Announces Preliminary Results Of Overseas Clinical Trials Of Two Glaucoma Drug Candidates; DE-092 Efficacy Insufficient 2/14/2006 2:51:27 PM